PRMT5
Assets acting on this target.
- Notes
- original target text: PRMT5 inhibitor
Protein arginine methyltransferase 5 (PRMT5) is an enzyme that adds methyl groups to arginine residues on histone proteins and many other cellular proteins, thereby influencing gene transcription, RNA splicing, and DNA damage repair. Because PRMT5 activity supports the proliferation of many cell types, particularly rapidly dividing cancer cells, its enzymatic function has become a target for pharmacological inhibition. A key biological rationale for this approach centers on tumors that carry deletion of the neighboring gene MTAP, which is frequently co-deleted with a tumor suppressor locus in several solid tumors. Loss of MTAP causes accumulation of a metabolite that partially inhibits PRMT5, creating a dependency state in which further pharmacological suppression of PRMT5 selectively harms MTAP-deleted cancer cells while sparing normal tissue that retains MTAP. This concept, known as synthetic lethality, underlies interest in PRMT5 inhibitors as a way to achieve a therapeutic window in an epigenetic target that would otherwise be broadly essential and difficult to inhibit safely. Small-molecule inhibitors of PRMT5 are being explored primarily in oncology, with particular relevance to cancers defined by this specific genetic deletion, illustrating a broader strategy of exploiting tumor-specific metabolic vulnerabilities rather than targeting a pathway unique to cancer cells alone.
Related mechanisms
PRMT5 drugs compared
6 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| AZD3470 | AstraZeneca | small molecule | Phase 1/2 | Not recorded |
| BAY 3713372 | Bayer, Suzhou Puhe BioPharma Co., Ltd. | small molecule | Phase 1/2 | Not recorded |
| TNG456 | Tango Therapeutics | small molecule | Phase 1/2 | Phase 1/2 in Glioblastoma; Phase 1/2 in Non-Small Cell Lung Cancer |
| Vopimetostat | Tango Therapeutics | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer; Phase 1/2 in Pancreatic Ductal Adenocarcinoma |
| HSK41959 | Haisco Pharmaceutical Group | small molecule | Phase 1 | Not recorded |
| IDE892 | IDEAYA Biosciences | small molecule | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer |